At CPAC we generate patient-derived organoids from a range of cancer types, including prostate and bladder cancers, to evaluate drug sensitivities and guide personalised selection of treatment as disease progresses. We perform real-time imaging, and conditioned media analyses, together with end-point metabolic, viability, and histopathological analyses to determine the effect of each compound on cancer organoids.
FOLLOW US
